title: Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.
abstract: Vascular disrupting agents (VDAs) are able to affect selectively tumour endothelial cell morphology resulting in vessel occlusion and widespread tumour cell necrosis. However, single-agent antitumour activity of VDAs is typically limited, as tumour regrowth occurs rapidly following drug treatment. To improve the therapeutic effectiveness of VDAs, we investigated liposomal targeting using ZD6126 as a model VDA. ZD6126 is a phosphate-prodrug of the tubulin-binding vascular disrupting agent ZD6126 phenol. ZD6126 was encapsulated into long circulating PEG-liposomes for passive targeting and PEG-liposomes conjugated with peptide ligands containing the RGD-motif for active targeting to alpha(v)-integrins on tumour endothelial cells. ZD6126 could be stably encapsulated, and liposomes displayed minimal leakage in vitro (<10% in 3 weeks). In vivo, upon intravenous injection, free ZD6126 was rapidly converted into ZD6126 phenol, which was cleared from the circulation within minutes. In contrast, ZD6126 encapsulated into either RGD-targeted or PEG liposomes showed prolonged blood circulation times (t(1/2)=10 h), and ZD6126 phenol exposure was also prolonged (t(1/2)=8 h). Both liposomal formulations displayed tumour accumulation plus hepatosplenic uptake by local macrophages. The altered pharmacokinetics and tissue distribution profiles of both liposomal ZD6126 formulations resulted both in single-dose and multiple-dose regimes, in improved therapeutic efficacy in established murine B16.F10 melanomas compared with free ZD6126. The passively and actively targeted liposomes showed equal antitumour efficacy, indicating that delivery of ZD6126 to the tumour tissue may suffice to disrupt tumour blood vessels without the need for specific targeting to the tumour endothelium.
authors.affiliation: Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
authors.forename: M H A M
authors.initials: MH
authors.lastname: Fens
authors.forename: K J
authors.initials: KJ
authors.lastname: Hill
authors.forename: J
authors.initials: J
authors.lastname: Issa
authors.forename: S E
authors.initials: SE
authors.lastname: Ashton
authors.forename: F R
authors.initials: FR
authors.lastname: Westwood
authors.forename: D C
authors.initials: DC
authors.lastname: Blakey
authors.forename: G
authors.initials: G
authors.lastname: Storm
authors.forename: A J
authors.initials: AJ
authors.lastname: Ryan
authors.forename: R M
authors.initials: RM
authors.lastname: Schiffelers
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry; D008081:Liposomes; D008264:Macrophages / Q000187:drug effects; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014471:Umbilical Veins
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; C455219:N-acetylcochinol-O-phosphate; D009943:Organophosphorus Compounds
references.citation: Biochemistry. 1998 Sep 15;37(37):12875-83
references.pmid: 9737866
references.citation: Nat Rev Cancer. 2006 Aug;6(8):583-92
references.pmid: 16862189
references.citation: Arthritis Rheum. 2003 Jul;48(7):2059-66
references.pmid: 12847701
references.citation: Nat Rev Cancer. 2005 Jun;5(6):423-35
references.pmid: 15928673
references.citation: Oncologist. 2003;8 Suppl 2:17-24
references.pmid: 13679592
references.citation: Anticancer Res. 2002 May-Jun;22(3):1453-8
references.pmid: 12168822
references.citation: Neoplasia. 2005 Feb;7(2):118-27
references.pmid: 15802017
references.citation: Gynecol Oncol. 2005 Jan;96(1):10-8
references.pmid: 15589573
references.citation: Breast Cancer Res. 2002;4(3):95-9
references.pmid: 12052251
references.citation: Cancer Res. 1988 Sep 1;48(17):4827-33
references.pmid: 3409223
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: Int J Cancer. 2002 Nov 1;102(1):70-4
references.pmid: 12353236
references.citation: Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):164-71
references.pmid: 12007956
references.citation: Semin Oncol. 2004 Dec;31(6 Suppl 13):16-35
references.pmid: 15717736
references.citation: Clin Cancer Res. 2002 Jun;8(6):1974-83
references.pmid: 12060643
references.citation: Clin Cancer Res. 2005 Apr 1;11(7):2720-6
references.pmid: 15814654
references.citation: J Exp Med. 1985 Mar 1;161(3):475-89
references.pmid: 3973536
references.citation: J Clin Oncol. 2006 Apr 1;24(10):1491-8
references.pmid: 16574998
references.citation: Int J Cancer. 2002 Dec 10;102(5):469-75
references.pmid: 12432548
references.citation: Nature. 2005 Jul 28;436(7050):568-72
references.pmid: 16049491
references.citation: Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1497-502
references.pmid: 12459377
references.citation: Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1512-7
references.pmid: 12459379
references.citation: J Natl Cancer Inst. 2007 Nov 21;99(22):1724-8
references.pmid: 18000220
references.citation: Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20
references.pmid: 15701823
references.citation: Biochim Biophys Acta. 1997 Jun 12;1326(2):236-48
references.pmid: 9218554
references.citation: Pharm Res. 2005 Jul;22(7):1117-20
references.pmid: 16028012
references.citation: Neoplasia. 2004 Mar-Apr;6(2):150-7
references.pmid: 15140404
references.citation: Cancer Res. 2003 Mar 1;63(5):1144-7
references.pmid: 12615734
references.citation: Semin Oncol. 2004 Dec;31(6 Suppl 13):161-81
references.pmid: 15717742
references.citation: Cancer Res. 2002 Nov 15;62(22):6371-5
references.pmid: 12438217
references.citation: Cancer Invest. 2002;20 Suppl 2:22-9
references.pmid: 12442346
references.citation: Science. 2004 Mar 19;303(5665):1818-22
references.pmid: 15031496
references.citation: Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):835-42
references.pmid: 15701874
references.citation: Cancer Res. 2000 Mar 15;60(6):1761-5
references.pmid: 10749151
references.citation: Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1233-40
references.pmid: 15519796
references.citation: Bioorg Med Chem. 2007 Jan 15;15(2):605-15
references.pmid: 17070061
references.citation: J Control Release. 2003 Aug 28;91(1-2):115-22
references.pmid: 12932643
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: J Clin Oncol. 1998 Jul;16(7):2445-51
references.pmid: 9667262